Clinical Benefit and Drug Revenues: a Retrospective Study of Oncology Drugs Approved Between 1995 and 2020
Publication date
Authors
DOI
Document Type
Master Thesis
Metadata
Show full item recordCollections
License
CC-BY-NC-ND
Abstract
Keywords
added therapeutic benefit; cost-effectiveness assessment; clinical evidence; health technology
assessment; regulation; reimbursement; relative-effectiveness assessment; drug revenues; oncology; orphan drugs; conditional market authorization; approvals under exceptional circumstances;